Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 84
Summary
- Conditions
- Advanced or Metastatic Breast Cancer
- Advanced Solid Malignancy
- AKT1
- Cervical Cancer
- Endometrial Cancer
- Tumour Response
- ER Positive
- PTEN
- HER2 Positive
- Ovarian Cancer
- Pharmacodynamics
- Pharmacokinetics
- PIK3CA
- Safety and Tolerability
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies.
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies.
Tracking Information
- NCT #
- NCT01226316
- Collaborators
- Not Provided
- Investigators
- Study Director: Gaia Schiavon, MSD AstraZeneca Principal Investigator: Udai Banerji, MD, PhD Institute of Cancer Research, United Kingdom
Get Well Soon